Biosimilar “Interchangeability” Standard Is Double-Edged Sword For Generics

The interchangeability standard for follow-on biologics set out in Senate legislation creates a relatively smooth pathway for generic firms to seek approval of such products, but could also lead to an extended struggle to win acceptance for such products in the marketplace